97760-99-1 Usage
General Description
4-Cyano-3-(trifluoromethyl)acetanilide is a chemical compound with the molecular formula C10H8N2O2F3. It is an organic compound and a derivative of acetanilide. 4-Cyano-3-(trifluoromethyl)acetanilide is commonly used in the synthesis of pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of dyes, pigments, and other fine chemicals. The presence of the cyano and trifluoromethyl groups in the structure makes it a valuable building block for the synthesis of complex organic molecules. 4-Cyano-3-(trifluoromethyl)acetanilide has various potential applications in the fields of medicinal chemistry, chemical research, and industrial production.
Check Digit Verification of cas no
The CAS Registry Mumber 97760-99-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,7,6 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 97760-99:
(7*9)+(6*7)+(5*7)+(4*6)+(3*0)+(2*9)+(1*9)=191
191 % 10 = 1
So 97760-99-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H7F3N2O/c1-6(16)15-8-3-2-7(5-14)9(4-8)10(11,12)13/h2-4H,1H3,(H,15,16)
97760-99-1Relevant articles and documents
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
Hamann, Lawrence G.,Manfredi, Mark C.,Sun, Chongqing,Krystek Jr., Stanley R.,Huang, Yanting,Bi, Yingzhi,Augeri, David J.,Wang, Tammy,Zou, Yan,Betebenner, David. A.,Fura, Aberra,Seethala, Ramakrishna,Golla, Rajasree,Kuhns, Joyce E.,Lupisella, John A.,Darienzo, Celia J.,Custer, Laura L.,Price, Jennifer L.,Johnson, James M.,Biller, Scott A.,Zahler, Robert,Ostrowski, Jacek
, p. 1860 - 1864 (2008/02/04)
Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.
